Federal Circuit affirms invalidation of two Illumina patents
The US Court of Appeals for the Federal Circuit has knocked out two patents belonging to biotechnology company Illumina following a challenge by Intelligent Bio-Systems.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
2 February 2021 Biotech company Illumina has won a dispute with Columbia University, after the Court of Appeals for the Federal Circuit backed an earlier ruling that the university’s DNA-sequencing patents were invalid.
2 February 2021 Biotech company Illumina has won a dispute with Columbia University, after the Court of Appeals for the Federal Circuit backed an earlier ruling that the university’s DNA-sequencing patents were invalid.
2 February 2021 Biotech company Illumina has won a dispute with Columbia University, after the Court of Appeals for the Federal Circuit backed an earlier ruling that the university’s DNA-sequencing patents were invalid.